Hook and thesis
The market has overreacted to Sjögren's-related headlines, pushing argenx (ARGX) into technically oversold territory and creating a tactical opportunity. Shares are trading at $813.97 after a recent pullback from a 52-week high of $1,072.75, and momentum indicators suggest the downside is getting stretched: the RSI reads 23.59 and the MACD is deeply negative (-30.34 with a -16.13 histogram). That combination often precedes a mean reversion in high-quality clinical biotech names that still have intact commercial growth and pipeline optionality.
My trade idea is a disciplined long: enter at $815.00, stop at $720.00, and target $1,150.00. This is a swing trade with a mid-term bias and a longer-term stretch objective - designed to capture a rebound fueled by product momentum, partnership expansions, and improving investor sentiment as headline noise fades.
What argenx does and why the market should care
argenx is a global immunology company focused on severe autoimmune diseases. Its commercial franchise centers on VYVGART (efgartigimod) and variants such as VYVGART Hytrulo, which have shown traction across indications like myasthenia gravis (MG) and CIDP. The company now operates across the United States, Japan, EMEA, and China, and management has signaled an ambition to build a broader immunology platform through M&A and internal development.
Why this matters: VYVGART is a recurring-revenue product in a category where switching costs and clinical evidence favor incumbents. Recent real-world data presented at neuromuscular meetings showed deeper and earlier responses in MG when treatment is initiated sooner, and one-year durability in certain subgroups. Strong commercial execution and broadened formulation partnerships materially affect top-line growth and royalty flows.
Hard numbers that support the setup
- Current price: $813.97; previous close: $818.63.
- Market cap: $51,187,398,817 (about $51.19B).
- Valuation multiples on the snapshot: P/E ~29.52 and P/B ~6.02.
- Trading range: 52-week high $1,072.75 (09/02/2026) and 52-week low $661.85 (03/20/2026).
- Technicals: SMA-10 $916.15, SMA-20 $946.10, SMA-50 $956.12; EMA-9 $895.33, EMA-21 $933.18, EMA-50 $941.65 - price sits well below short- and mid-term averages.
- Momentum: RSI 23.59 (oversold); MACD line -30.34, signal -14.21, histogram -16.13 (bearish momentum but ripe for mean reversion).
- Liquidity and shorting: average volume ~518,471 (2-week), float ~62.76M shares, and short interest on 09/15/2026 was 1,313,174 shares with days-to-cover ~6.31 - enough short pressure to exacerbate moves but also set up a short-covering bounce if sentiment flips.
Why I think the Sjögren's selloff is overdone
First, recent corporate developments point to durable commercial momentum and expanding upside outside of any single readout. On 10/07/2026, Halozyme expanded its ENHANZE collaboration with argenx, increasing exclusive targets from six to eight and adding milestone/royalty economics - a sign that partners are willing to double down on formulations tied to argenx programs. Second, argenx completed the acquisition of Forte Biosciences on 08/27/2026, bringing FB102 (anti-CD122) into the pipeline and diversifying the company’s immunology exposure. Third, clinical presentations on 09/29/2026 reinforced VYVGART's real-world effectiveness across MG and CIDP, which supports ongoing uptake and pricing power.
Put together, these items argue that a single indication swing - Sjögren's worries in this case - should not derail the firm's broader growth trajectory. Market cap sits at $51.19B while many growth drivers remain intact; the current P/E around 29.5 reflects a premium but is not absurd for a company with a commercially proven product and multiple near-term catalysts.
Valuation framing
At $51.19B market cap and roughly 62.89M shares outstanding, the stock trades materially below recent highs but well above the March low of $661.85. A mid-term normalization back toward the $950 area would still leave the stock below recent highs and within a valuation range consistent with above-market growth expectations. Analysts remain constructive; one recent piece noted a consensus push toward $1,200 targets, which implies meaningful upside from current levels but also signals that upside is already reflected in part in consensus forecasts.
Catalysts to watch (2-5)
- Commercial cadence and quarterly sales prints - evidence of continued VYVGART uptake across MG and CIDP will re-rate the stock.
- Further ENHANZE-related licensing milestones or expansion announcements that generate near-term revenue/royalty visibility (related Halozyme collaboration news - 10/07/2026).
- Positive real-world evidence or broader label expansion for VYVGART from ongoing post-marketing/Phase 4 studies.
- Pipeline binary events tied to FB102 or other internal assets that diversify revenue potential (post-acquisition integration milestones after 08/27/2026).
- Possible short-covering rallies if headline risk subsides and volume shifts - short interest and recent heavy short volumes create the technical setup for a squeeze.
Trade plan - exact actionable rules
Entry: $815.00 (aggressive, near current price).
Stop loss: $720.00 (hard stop - a break below this level would indicate a deeper re-pricing and invalidate the tactical thesis).
Primary target: $1,150.00 (stretch target - aligns with recovery toward the upper end of the 52-week range and analyst optimism).
Time horizon: the trade is intended as a swing across two time buckets: near mid term and extended recovery. Specifically, manage the position with a view to mid term (45 trading days) for an initial take-profit at $950.00 and hold toward a longer re-rating at $1,150.00 out to long term (180 trading days) if catalysts materialize.
Rationale: the mid-term (45 trading days) target at $950 captures a mean reversion to below the 52-week high but above the 50-day SMA, while the long-term (180 trading days) target assumes sustained commercial momentum, favorable data flow, and continued partnership monetization. If the price hits $950, consider taking partial profits and tightening stops to protect gains. If $720 is breached on a close, exit to cut losses.
Risks and counterarguments
Below are the principal risks that could derail this trade:
- Clinical/regulatory disappointment: Biotech names are binary-sensitive. Any negative results or regulatory setbacks related to Sjögren's or other late-stage assets would likely push shares materially lower.
- Commercial execution risks in China and other markets: The company has noted headwinds in China in recent commentary; a slowdown in a major geography would pressure growth assumptions.
- Valuation compression: With a market cap near $51.19B and a P/E around 29.5, multiple contraction is possible if revenue growth misses expectations or macro risk appetite for growth stocks wanes.
- Heavy shorting and volatility: Elevated short volumes and a days-to-cover north of 6 create two-way risk: the same short pressure that amplifies a rally can also accelerate a downside move if negative news arrives and shorts hold their positions.
- Integration risk: The Forte Biosciences acquisition (completed 08/27/2026) adds clinical assets but also integration and execution risk that could distract management or consume capital.
Counterargument: The primary bear case is that Sjögren's outcomes or related safety/efficacy signals are worse than the market expects, materially impacting label prospects and physician adoption. That is a valid path that could justify further multiple compression. However, the balance of recent operational signals - partnership expansion with Halozyme on 10/07/2026, positive real-world VYVGART data on 09/29/2026, and an acquisition that diversifies immunology exposure on 08/27/2026 - suggests the company has multiple irons in the fire beyond any single readout. Traders who prefer less event risk should size accordingly or wait for confirmatory price action above $950 before adding size.
Conclusion and what would change my mind
Short-term technicals show ARGX is oversold and susceptible to a bounce, while the fundamental picture remains constructive: a commercial product with growing real-world evidence, an expanded ENHANZE collaboration, and strategic M&A to broaden the pipeline. For disciplined traders, a long entered at $815.00 with a $720.00 stop and a primary target of $1,150.00 represents a well-defined asymmetric trade - limited downside (relative to stop) with meaningful upside if catalysts align.
I would change my bullish tactical stance if any of the following occur: a credible negative Sjögren's outcome that directly and demonstrably reduces addressable market for VYVGART; quarter-on-quarter deterioration in product uptake or pricing in key markets; or a clear failure to integrate Forte that materially increases burn without pipeline progression. Conversely, accelerating revenue prints, additional formulation or licensing wins, or further positive real-world evidence would validate the thesis and prompt a larger, conviction-based position.
Key near-term dates to monitor
- 10/07/2026 - Halozyme expanded ENHANZE collaboration (positive partnership signal).
- 09/29/2026 - New clinical and real-world data presented reinforcing VYVGART utility.
- 08/27/2026 - Acquisition of Forte Biosciences completed - watch integration updates and FB102 development milestones.
Trade idea summary: Long ARGX at $815.00, stop $720.00, target $1,150.00. Swing bias - initial mid-term objective at $950 within 45 trading days, with a longer hold to $1,150 into 180 trading days if commercial/pipeline catalysts play out.